Univariate analysis (Logrank) | Multivariate analysis (Cox) | |||||
---|---|---|---|---|---|---|
Characteristics (reference) | HR | 95% CI | P-value | HR | 95% CI | P-value |
Patient Characteristics | ||||||
Gender (male vs female) | 1.3 | 0.6-2.7 | 0.6 | - | - | - |
Age (≥ 60 vs < 60 years) | 0.5 | 0.3-0.8 | 0.005 | - | - | - |
Pretreatment hemoglobin level (< 120 vs ≥ 120 g/L) | 0.97 | 0.6-1.6 | 0.9 | - | - | - |
Initial weight loss (≥ 10% vs < 10%) | 1.4 | 0.8-2.2 | 0.2 | 1.5 | 0.9-2.7 | 0.1 |
Dysphagia (mild vs liquid) | 1.3 | 0.8-2.3 | 0.3 | - | - | - |
Karnofsky Performance status (≤ 80 vs 90-100) | 2 | 1.25-3.3 | 0.008 | 1.7 | 0.99-3 | 0.06 |
Tumor Characteristics | ||||||
Histology (SCCE vs ACE) | 1.15 | 0.7-1.9 | 0.6 | - | - | - |
T Stage (3-4 vs 1-2) | 1.1 | 0.6-2 | 0.8 | - | - | - |
N Stage (1 vs 0) | 1.4 | 0.9-2.4 | 0.15 | - | - | - |
M stage (1 vs 0) | 1.8 | 1.01-3.1 | 0.04 | - | - | - |
Treatment-related Characteristics | ||||||
Objective response to CRT (no vs yes) | 3.3 | 1.9-5.9 | < 0.0001 | 3.3 | 1.6-6.8 | < 0.001 |
Definitive CRT vs Preoperative CRT | 2.5 | 1.4-5.0 | 0.005 | 7.1 | 3.6-13.1 | < 0.0001 |
Antibodies | ||||||
Anti-p53 (positive vs negative) | 1.8 | 1.03-2.9 | 0.04 | 2 | 1.05-2.8 | 0.04 |
Anti-Ras (positive vs negative) | 0.8 | 0.5-1.5 | 0.5 | - | - | - |